

Index

a

- AAFE. *see* absolute average fold error
- α/β hydrolase enzyme family 687
- absolute average fold error (AAFE) 472
- absolute chirality 554
- absorption, distribution, metabolism, and excretion (ADME) 4, 5, 8, 135, 167, 332, 426, 439, 454, 492, 539, 577, 705
 - challenges 388
 - properties 519
- acetamido group 674
- 2-acetylamino-1,3,4-thiadiazol-5-sulfonamide 203
- acetylation 193
- acetylcholine 515–517, 519, 520, 539, 543
 - dysfunction of 515
- acetylcholinesterase (AChE) 515
- N*-acetyl derivative 537
- N*-acetylneuraminic acid 653, 659
- AChE. *see* acetylcholinesterase (AChE)
- AChE inhibitors 516
- acidic compound 476
- acids 476
 - pharmacokinetics of 476
- ACS. *see* acute coronary syndrome (ACS)
- active site
 - topology of 578
- acute coronary syndrome (ACS) 549, 568
- acylurea 638, 639
- adenosine triphosphate (ATP)-competitive kinase inhibitor 19
- adenylyl cyclase (AC) 599
- ADHD syndrome 516
- ADME. *see* absorption, distribution, metabolism, and excretion (ADME)
- ADMET. *see* adsorption, distribution, metabolism, excretion, and toxicology (ADMET)
- adrenergic (AR) receptor agonists 517
- adsorption, distribution, metabolism, excretion, and toxicology (ADMET) 4, 5, 173, 335
- AFE. *see* average fold error
- affinity-based screening methods 402
- aging 186, 196, 401, 516
- agomelatine 187
- airway smooth muscles 575
- Akt1 kinase 47
- aldehyde 376, 503, 553–555, 561
- allosteric mechanism 402
- allosteric modulation 17
 - of ligand-gated ion channels 116
- allosteric modulator 115, 116
- alpha lipoic acid (ALA) 191
- alpha-shape geometry 56
- alprazolam 228
- Alzheimer's disease (AD) 14, 190, 198, 249, 515, 547
- amide, pharmacophoric region of 754
- amiloride analogs 245
- amiloride HCl 246
- amino acid-conjugated acyloxy ester prodrugs 668
- γ -aminobutyric acid (GABA) 192, 193, 227, 229, 516, 517
- aminofluorocoumarin (AFC) 293
- 2-amino-8-hydroxyquinoline 251
- 5-amino-8-hydroxyquinoline 251
- 3-amino-4-methyl-*N*-methoxybenzamide (AMMB) 264
- aminooxazole, rapid hydrolysis of 524
- amyloid hypothesis 14
- analogization 230
- analog synthesis 561
- ancient drugs 226
- andorgrapholide 118
- angiotensin-converting enzyme (ACE) inhibitor 161

- angiotensin I (Ang I) 691
- angiotensin II (Ang II) 691
- anisotropic distribution, of electron density 387
- Ant colony methods 444
- ante-drug approaches 575
 - design concept of 587
- antibacterial drugs 749, 750
 - β -lactams 749
 - fluoroquinolones 749
 - oxazolidinones 749
- antigen–antibody interactions 404
- antihistamines, first-generation 201
- anti-influenza drug 671
- antimalarial drugs 749, 750
 - NITD-609 751
- antimuscarinic activity 547
- antimuscarinic project 547
- antiplatelet 549
 - therapy 549
- antipsychotic drugs
 - structural analogs 228
- antithrombin III activation 249
- antitubercular drugs 749, 750
 - ethambutol 749
 - ethionamide 749
 - isoniazid 749
 - pyrazinamide 749
- antiviral efficacy 670
- α -OH isomer 560
- apoptosis 401
- approved drugs 547
- aromaticity 117
- artemisin 318, 319
- artemisinin 723, 724
- arterial thrombosis 548
- aryl himbacine derivatives
 - pharmacokinetic data for 550
 - synthesis of 562
- aspirin 37, 42, 226, 289, 567–569
- assays 494
 - high-content/phenotypic 494
 - pharmacology 494
- astemizole 176
- AstraZeneca 14, 456
 - guidebook, lead generation addressed by 57
- atherothrombosis 549
- autofluorescence 70, 406, 412
- automatic design of lead compound 443
- average fold error (AFE) 472
- avian viruses 651
 - H5N1 651
 - H7N9 651
 - H9N2 651
- 1,4-azaindoles 738
- b**
- backscattering interferometry (BSI) 417, 418
- β_2 -adrenoceptor (β_2 AR) 575
 - first/second-generation agonists, examples of 576
- balancing quality 443
 - with diversity 443–445
 - selections of compounds, from library 446
- β -amyloid 515
 - peptide 198
- β_2 AR. *see* β_2 -adrenoceptor
- β_2 AR agonists 575
 - AstraZeneca lead generation exercises for 587
 - library design strategy 592
 - potency and intrinsic activity at human 588, 589
 - first-generation of 575
 - isoprenaline 575
 - lead generation exercises for 577
 - benzyl amine side chain 584
 - data for indane derivatives 579
 - dichloro-benzyl amine 584
 - evolution of initial hit structure 583
 - evolution of initial lead generation hit 582
 - evolution of medicinal chemistry design 586
 - glucuronidation 585
 - guinea pig trachea data for indane derivatives 578
 - 8-hydroxyquinolone catechol 578
 - lipophilicity 578
 - oral absorption 584
 - plasma glucose, changes in 582
 - plasma lactate, changes in 582
 - plasma potassium, changes in 582
 - salt bridges 584
 - structure-based drug design (SBDD) 578
 - structure of agonist-bound 578
 - sulfonamide 584
 - therapeutic index (TI) 585
 - long-acting β_2 AR agonist (LABA) 575
 - rationalization of agents, strategies for 576
 - salbutamol 575
 - second-generation of 575
 - terbutaline 575
- β_2 AR systemic-mediated side effects 576
- Bcl-2 Inhibitors 344
- benzodiazepine receptor 231
- benzoic acid 640

benzoquinolizines 406
 benzoxazole analogs 167
 benzoxazole pocket 167
 benzyl 4-(cinnamoyloxy) *but*-2-ynoate, thermal cyclization of 561
 benzylimidazole-type derivatives 517
 betamimetic compounds 588
 beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) 14, 30, 54
 BICLAIM library 172
 Bill and Melinda Gates Foundation 717
 binding mode
 – dependency 390, 391
 – switch in response 391
 binding pocket 497
 bioavailability 5, 224, 225, 467, 469, 587, 736
 – oral 143, 211, 264, 557, 671, 697
 biochemical assay 458
 biogenic amine ligands 41
 bioisosteres 16
 bioisosteric replacement 160
 biolayer interferometry (BLI) 49
 biological
 – activity 73, 160, 167, 230, 293, 351, 706, 710, 748
 – assays 137, 165, 291, 348, 592, 634
 – processes 190, 367, 381
 – samples 65, 66, 68, 82
 – screening cascade 20
 – target 16, 19, 37, 86, 223, 266, 414, 722, 758
 bioluminescence 70
 biomarker 63, 199, 458
 BioPrint database 222
 biosensor 48, 404–406, 418
 BIOSER database 441
 biotin 40, 81
 black-box warnings, for drugs 26
 blood-brain barrier (BBB) 429
 – penetration 453
 β -OH isomer 560
 Born–Haber cycle
 – of solvation/desolvation 368
 bovine serum albumin (BSA) 632
 bradykinin 690–692
 – metabolism 705
 – signaling 713
 bronchodilators 575, 576, 589
 BROOD software 174, 428
 BSA. *see* bovine serum albumin (BSA)
 Buchwald coupling reaction 754
 bupropion 234

c

c 159, 161, 163, 371
 – enthalpy of binding 371
 – entropy changes 371
 – Gibbs free energy 371
 C_{3a}–C_{9a} bond formation, facial selectivity of 555
 Caco classification 706
Caenorhabditis elegans 290
 C_{3a} hydrogen 555
 Cambridge Structural Database (CSD) 357
 cancer 67, 249, 343, 467, 717
 – clioquinol-induced 249
 – drug for 467
 – modulators of Wnt signaling 75
 – therapy 193, 194
 candidate drugs (CD) 451
 candidate drugs (CDs)
 – for preclinical studies 373
 cannabinoid receptors 210
 canonical sialidase structure 657
 carbohydrate 405, 598, 660, 664, 671
 carbonic anhydrase 203
 carbonyl groups 211, 363, 386, 524, 528, 554, 564, 639, 663, 665, 700
 carboxylic acid 146, 149, 150, 162, 167, 554, 668, 672, 698, 700, 702, 705
 carboxypeptidase enzymes 690
 cardiac hypertrophy 691
 cardiovascular disease 717
 carrier-mediated transport pathway 668
 C-5' aryl derivatives 558
 case studies 597, 727
 – amiloride analogs as inhibitors
 – – of urokinase-type plasminogen activator 245, 246
 – antiparasmodial compounds, new, discovery of 239
 – bupropion 234, 235
 – chimera strategy 197–201
 – chlorothiazide 235
 – chlorpromazine 235
 – clioquinol 249, 251
 – dihydroorotate dehydrogenase (DHODH) 727, 728
 – drugs acting on central nervous system targets as leads for non-CNS targets 241, 242
 – flavonoids with an oligopolysulfated moiety 246–249
 – – as new class of anticoagulant agents 247
 – – strategies used for development of new anticoagulant 248

- fused strategy 192–197
- G-protein-coupled receptor 81
 - (GPR81) 598
- on HSP-90
 - – dissociation constant, changes in 385
 - – interstitial waters, and usefulness 381–385
- hybrid strategy 190–192
- methylation in SOSA strategy of drug design 237–239
- mexiletine derivatives as orally bioavailable inhibitors
 - – of urokinase-type plasminogen activator 242–245
- minaprine analogs 236, 237
- morphine analogs 232
- propranolol 235, 236
- sildenafil (Viagra) 232, 233
- sulfonamides 231
- thalidomide analogs 233, 234
- viloxazine analogs 237
- warfarin 232
- whole-cell screening 728, 729
- catalytic triad 687
 - Asp372 687
 - His429 687
 - Ser150 687
- catechol binding site 576
- cathepsin A (CatA) 687
 - bradykinin metabolism 711
 - catalytic mechanism of 694, 696
 - covalent-reversible inhibitor of 693
 - deficiency 689
 - inhibition 687, 690
 - inhibitors 710
 - knockout mice 689
 - lead identification 702
 - link to cardiovascular disease 691
 - natural products and synthetic peptides as inhibitors of 691
 - pharmacological inhibition of 691
 - protein 705
 - proteolytic activity of 689
 - proteolytic mechanism 688
 - substrates of 690
 - – angiotensin I 690
 - – bradykinin 690
 - – endothelin 1 690
 - – oxytocin 690
 - – substance P 690
- cathepsin A enzyme 687
 - catalytic mechanism 687
 - natural products and synthetic peptides as inhibitors of 690
 - structural and catalytic functions of 689
 - structural biology 687
 - tissue distribution and substrates 689
- cathepsin L (CatL) 386, 687
 - S3-pocket 387
- cathepsin S (CatS) 687
- CB₁R antagonists 214
- CCR5 antagonists 9
- CD. *see* candidate drugs
- CDK 2 inhibitor crystal structures 427
- celecoxib 42
- cell-based replication assays 670
- cell–cell interaction 67
- cell–extracellular matrix interaction 67
- cell permeability 39
- cells cultured in 2D/3D 66, 67
- cell-viability assay 292, 293
 - reaction schemes 292
- central nervous system (CNS) 430, 453
 - disorders 190, 717
- central nervous system (CNS)
 - acting agents 213
- C₆ -ethyl pyridine derivative 557
- checkpoint kinase-1 (Chk-1 kinase)
 - inhibitors 171
- ChEMBL database 222
- chemical biology 22
- chemical biology platforms 362
- Chemical European Molecular Laboratory (ChEMBL) 318
- chemical feasibility 21
- chemical fingerprints 505
- chemical framework of ligand 390, 391
- chemical scaffold, refined 585
- chemical space 43, 437, 443
 - plots 441
- chemical tractability assessment, by *in silico* approaches 7, 38, 54
 - discrimination functions, and validation sets 55, 56
 - pocket-finding algorithms 54, 55
 - simulation-based methods
 - – for identifying interaction potentials 56
- chemistry-driven target discovery 65
- chemistry-driven target identification 64
- chemogenomics 160, 174
 - approaches 160, 175, 177
- chemoinformatics tools 310
- chemotherapy 37
- chemotypes 14, 64
- chiral chromatography 524
- chloronaphthyl sulfonamide 391
- chloroquine 724

- chlorothiazide 235
- chlorpromazine 229, 235, 490
- cholinergic hypothesis 515
- cholinesterases 687
- chronic obstructive pulmonary disease (COPD) 575
- CILG. *see* competitive intelligence-based lead generation (CILG)
- CILG hybrid strategy 199
- circular dichroism (CD) spectroscopy 283
- classic phenotypic screening 293, 294
- click chemistry 107, 108
- “cliff-forming” compounds 337
- clinical doses 471–475
- clinical trials 25, 63, 143, 164, 194, 222, 233, 290, 294, 319, 451, 471, 490, 492, 570, 675, 718, 750
- clioquinol 249, 251
- clozapine 228
- clustering 615
 - algorithms 334
 - computational chemist, manual assessment of 616
 - GPR81 results 617
 - output against hypothetical chemical space 334
 - pharmacophores 616
- cMAD to eD2M ratio 478
- C₃ methyl group 555
- C₆ monoalkyl-substituted derivatives 556
- C₅ monoaryl derivatives 556
- CNS. *see* central nervous system
- CNS MPO (CNS multiparameter optimization) 342
- coagulation cascade factors 388
- cocktails of pure, high-quality compounds 121
- C9 octanoyl ester 669
- cofactors 41
- collaborative approaches 311, 319
- collaborative initiatives 307
- collection enhancement programs 102
- color codes 24
- combination therapy 225, 755
- combinatorial biosynthesis 119
- combinatorial chemistry 24, 107, 123, 164, 165, 167, 260, 262, 331, 346, 375
- combinatorial libraries 6, 101, 110–112, 119, 121, 165, 166, 242, 375
- communication 198, 308, 318, 543
- competitive intelligence (CI) based approach 184, 185–190
- competitive intelligence-based lead generation (CILG) 16, 184, 185
- compound collection screening 95
- compound libraries
 - from andorgrapholide 118
 - screening of 15
- compound property prediction 427–430
- compounds, biological data of 703
- compound selection 102, 602
 - virtual screening 602
- compound set enrichment (CSE) 608
 - cell batches 613
 - clustering 608
 - dispense failures 613
 - Kolmogorov–Smirnov test (KS) 608
 - maximum common substructure (MCS) 608
 - Murcko fragments 610
 - plate effects 613
- computational approaches 40, 43, 58, 152, 153, 386
 - virtual screening to identify novel H1R binders 153
- computational chemistry 114, 159–161, 163–165, 173
- computational geometry techniques 56
- computational rescaffolding tools 174
- concentration–response counterscreen 622
- concentration–response curves (CRCs) 336
- conformation 40, 162, 172, 349, 357, 358, 409, 556, 662, 708, 710
 - changes 353
 - constraints 441
 - selection 40
- consortia 307
- contemporary drug discovery 38
- cooperativity, in binding 391
- COPD. *see* chronic obstructive pulmonary disease
- cores 748, 749
 - 3D, spatially oriented 753
 - nonflat 751
- cost-cutting 24
- costs 309, 310
- coumarins 197
- counterscreen potency 622
- covalent inhibitors 27
 - crystal structure of 694
 - metabolic lability of 697
- COX inhibitors 160
- CRC dictionary of natural products 110
- CREATION of Leads 20
- creativity 308
- “cryptic” pockets 40
- Crystalead technique 184

- CSE. *see* compound set enrichment (CSE)
 Curatolo maximum absorbable dose (cMAD) 478
 cyanopyrrolidines 406
 cyclic acyldepsipeptides 350
 cyclobutoxy amides, properties of 541
 cyclobutoxy fused thiazoles, properties of 538
 cyclobutoxy linker 537
 cyclobutoxy spacer 531, 537
 – activities of compounds with 533
 cyclohexene scaffold 671
 cyclooxygenase (COX) inhibitors 37, 174, 175
 – bioisosteric replacements 175
 cyclopentane scaffold 673
 – guanidino group 674
 – influenza A virus N9 sialidase 673
 – Neu5Ac2en 673
 – stereochemistry 674
 cyclopropyl amide 498
 – SAR of 498
 cyclopropyl pocket 167
 cytotoxicity 16
 cynomolgus monkey model 553, 554, 561
 Cys-loop receptors 116
 cysteine-directed kinase inhibitors 42
 cytochrome
 – CYP3A4
 – – as indicator 706
 – – inhibition 705
 – CYP2B isozyme 559
 – CYP2D6 518
 – CYP450 ligand 521
 – inhibitions 210, 705
 – isoforms of 454
 – oxidation 548
 cytotoxicity 666
- d**
 daclatasvir 361
 D-amino acid oxidase (DAO) 391
 – inhibitors 392
 – interaction network 393
 – ligand efficient DAO fragment binders 393
 – templates 392
 – thermodynamic signature 392
 daughters 748, 749
 – from parents, generation of 751
 daylight fingerprints 333
 DCC. *see* dynamic combinatorial chemistry (DCC)
 DDI. *see* drug-drug interactions
 deacetylation 193
 O-debenzylation 554
de facto standard approach 43
 DEI. *see* drug efficiency index
 Delaunay triangulation 56
de novo design methods 439, 440, 442
 – “chemical space” plots 441
 – donepazil, to identify leads with 442, 443
 – generate new compound structures 439
 – property profiles and score plots 438
 2-deoxy-2,3-dehydrosialic acid 162, 163
 4-deoxy-4-guanidino-Neu5Ac2en 667
 4-deoxy-4-guanidino-neu5Ac2en 163
 descriptor fingerprint 441
 design-make-test-analyze (DMTA) 489
 – DMTA cycle 340, 490
 – results from 508
 design-make-test-analyze cycle (DMTA cycle) 23, 332, 452, 489
 – analyze: formulating sensible plans for next designs 502
 – – custom-weighted scoring 503
 – – H-bond donors/acceptors 503
 – – key questions to address within component of 506
 – – matched molecular pair analyses (MMPA) 503
 – – matched molecular pair, single moiety held constant 504
 – – pipeline pilot 503
 – – pocket-C_α overlay of USP14 structure, papain-like protease/ deubiquitinase structure 505
 – – polar surface area 503
 – – predictive models 503
 – – radar plot to visualize differences between compounds 506
 – – scoring schemes 503
 – – Site-Hopper 504
 – – structural chemistry 503
 – – ubiquitin aldehyde 503
 – – Vertex compounds 505
 – – Wilson analyses 503
 – candidate drug refinement/selection 489
 – design: what to make 496
 – – drug-likeness parameters 497
 – – hit-to-lead 496
 – – hydrophobicity 497
 – – key questions to address within component of 496
 – – lead generation design team, cartoon portrayal of 496, 500
 – – mGluR2 hit compound was expanded to reveal scope at R5 499
 – – molecular weight, higher 497

- polar groups, value of exploring 497
- SAR around a soluble epoxide hydrolase inhibitor hit compound 498
- historical perspectives 490
- chlorpromazine and dawning of golden age of pharmaceuticals 490
- crisper decision making 491
- drug discovery programs 491
- example of lead generation design/ testing cascade 491
- tracking board enables capture of design ideas 493
- *in vitro* ADME 492
- *in vitro* data 490
- *in vivo* data 490
- *in vivo* PK 490
- make: challenges and strategies for synthesis 501
- chemical transformations, accessibility of 501
- fable *The Mice In Council* 501
- key questions to address within component of 501
- organic synthesis, powers of 501
- results 508
- software platforms 492
- test 494
- ADME/PK 494
- assays arranged by generic classes, examples of typical 494
- control compounds 496
- high-throughput methods 496
- hit compounds, identification of 494
- key questions to address within component of 495
- positive/negative control 495
- representative compounds 496
- desirability functions 432–435
- developability classification system (DCS) 6
- developing project-customized 20
- diastereoselective synthesis 557
- diastereoisomers 582
 - separation of 582
- diazepam 228, 231
- dibasic compounds 590
 - medicinal chemistry design hypothesis, to explore potential 590
- dibasic oxazoline derivatives 524
- Diels–Alder reactions 112, 263, 555
- macrocycles, formed from 112
- protocol 562
- 1,5-dienyl hydride shift 561
- differential scanning fluorimetry (DSF) 49
- diffusion microkinetic theory 576
- difluorobenzene rings 699
- dihydroorotate dehydrogenase (DHODH) 722, 727
- dimethoxybenzyl amide 582
- DIO mouse model 214
- diosmin. 248
- dioxospirocycles 111
- direct binding assay (DBA) 405
 - approach 48
- discovery of vorapaxar (SCH 530348) 564
- disease-associated gene products 41
 - mediate interactions 41
- disease-associated protein gene products 42
- disease-associated target 41
- disease-modifying activity 37
- disease-relevant cells 63
- Diseases of the Developing World (DDW) 321, 322
- Diskhaler technology 668
- diversity 443–445
- diversity oriented synthesis (DOS) 16, 96, 107, 108, 109
 - concept of 103
 - Lewis-acid controlled 109
 - libraries 16
 - macroline-like compounds via 111
 - planning 109
- DMPK. *see* drug metabolism and pharmacokinetics (DMPK)
- DMTA. *see* design–make–test–analyze (DMTA)
- DNA-encoded libraries (DEL) 8, 15, 16, 96, 117, 119, 120, 259, 260
 - on biological targets of therapeutic interests, applications of 268–275
 - categories 262
 - overview 260–262
- DNA-encoded libraries technology (ELT) 8
- DNA-encoded peptide, libraries on resin 261
- DNA mimicking cores 16
- DNA-recorded synthesis 262
 - -assisted libraries 262–264
- DNA sequencing machines 260
- DNA structure 491
- DNA supercoiling assay 755
- DNA-tag 415
- DNA-templated synthesis (DTS) 262
 - -assisted libraries 264–266
- DNDi. *see* Drugs for Neglected Diseases Initiative
- donepazil 442
- donepezil 198, 443, 515

- DOS libraries 24
 - DPP-IV inhibitors 406
 - drivers, of selectivity and specificity 373, 374
 - Drosophila melanogaster* 290
 - drug 464
 - efficiency of 466
 - mode of administration 464
 - drugability, assessment of 21, 39
 - DrugBank database 756
 - drug design 451, 747
 - absorption, distribution, metabolism, and excretion (ADME) 454
 - AstraZeneca 456
 - biochemical assay 458
 - composite rules/guides for 465
 - costs of 451
 - data supporting technique 471
 - absolute average fold error (AAFE) 472
 - average fold error (AFE) 472
 - eD2M doses, matching 472
 - eD2M (mg) vs C_{min} normalized clinical dose (mg) 473, 474
 - fold error, absolute average values for eD2M 473
 - normalized observed clinical doses 472
 - drug–drug interactions (DDI) 454
 - eD2M model 472
 - concentration C_{max} 472
 - high-throughput screening (HTS) 451
 - hit-to-lead (H2L) 451
 - lead generation (LG) 451
 - lead identification 451
 - lead optimization (LO) 451
 - mode-of-action cell assays 458
 - mode of administration 464
 - multiobjective optimization in 466
 - multiparameter optimization (MPO) 467
 - optimizing properties 457
 - clogP (lipophilicity) 457
 - logD (logarithm of the octanol) 457
 - logD (water partitioning coefficient at pH 7.4) 457
 - phenotypic assays 458
 - physicochemical binding assays 458
 - profiling distribution, metabolism, and pharmacokinetics (DMPK) 454
 - properties in 452
 - biologically active molecule 453
 - design–make–test–analyze cycle (DMTA cycle) 452
 - drug-like molecules 453
 - lipophilicity 453
 - pharmacodynamic 452
 - pharmacokinetic 452
 - pharmacological 452
 - physicochemical 452
 - plasma protein binding 453
 - primary activity assays 453
 - rule-of-five 464
 - rule-of-three 464
 - rules for potency 457
 - biochemical assay 458
 - EC_{50} 457
 - enzyme assays 458
 - GI_{50} 457
 - group efficiency (GE) 459
 - IC_{50} 457
 - ligand efficiencies 463
 - ligand efficiency (LE) 458
 - strength of binding 457
 - various ligand efficiency metrics and their typical target range 460
 - rules for safety 462
 - GINI-like coefficient 463
 - kinase inhibitors 463
 - kinome screening, routine 463
 - secondary target pharmacology 463
 - safety in 454
 - hERG pIC_{50} vs. logD. A general trend for lipophilic compounds 455
 - Nav pIC_{50} vs. hERG pIC_{50} a trend for hERG inhibitors 455
 - SILE/LLE plot 461
 - *in silico* 467
 - time-dependent inhibition (TDI) 454
 - typical properties in oncology kinase projects 456
 - use of LLE and SILE in a project 461
- drug discovery 3, 63, 160, 184, 361, 717, 747
 - leads 547
 - organizations 38
 - product development partnerships (PDPs) 717
 - public–private partnerships (PPPs) 717
 - research 547
 - strategy 38
- drug–drug interactions (DDI) 454, 718
- profiles of 718
- drug efficiency (DE) 4, 5
- drug efficiency index (DEI) 4, 465
 - definition of 466
- drug failure
 - reasons for 467
- druggable 37
 - chemical matter 747
 - genome 42

- phenotype 291
- “Drug Guru” platform 439, 440
- “drug-like” chemical space *vs.* typical sizes of
 - corporate screening collections 346
- drug-like compounds 39
- drug-like density (DLID) metric 55
- drug-like molecules 39
- drug-likeness 361
- drug-like properties 310, 430
 - compound properties 430, 431
- drug-like space 3, 345
 - guidance, on physchem properties 5
- drug metabolism and pharmacokinetics (DMPK) 20, 332, 577
 - properties 13
 - and toxicity 24
- drug potency 27
 - influence hERG margins 26
- drug repositioning 226
- drug repurposing 226
- drug research and development 221
- drug safety 222, 332
- drugs as fragments 225
- drugs derived, from fragment-based drug
 - discovery efforts 134
- drug selectivity 222, 223
- Drugs for Neglected Diseases Initiative (DNDi) 717
- drugs in other drug 225
- drug targets 41, 687
 - hypothesis 37
- DScore 56
- dual HMGR-HDAC inhibitor 196
- dual-target design strategy 190
- dynamic combinatorial chemistry (DCC) 117, 121, 375, 376, 378, 555
- e**
- ebelactone B 687, 690
 - coadministration 713
- ECFP4 fingerprints 335
- economic viability 38
- ectopic lipid 598
- eD2M model 472
 - concentration $C_{\max}$ 472
 - determining properties that drive predictions for a series 474
 - changes in eD2M for acid, base 477
 - cMAD to eD2M ratio 478
 - cMAD to eD2M (mg/dose) ratio plotted *vs.* synthesis week for 479
 - Curatolo maximum absorbable dose (cMAD) 478
 - dosing interval 475
 - eD2M (mg/dose) plotted *vs.* synthesis week 478
 - hERG to free $C_{\max}$ ratio plotted *vs.* synthesis week 480
 - nonmetabolic elimination 476
 - T_{half} 475
 - flagging potential candidate drugs using 473
 - fold error, absolute fold error values for *vs.* $C_{\max}$ normalized clinical dose 475
 - *vs.* $C_{\max}$ normalized clinical dose 474
- EdoxabanTM 388, 390
- Ehrlich, Paul 37
- electromagnetic field intensity 405
- electron density maps 694
- electrostatic interactions 49, 369
- elitism 444
- emergency investigational new drug 668
- enabling biology 65
- enantiomers 186, 213, 502, 548, 552, 554, 733, 734, 736
- encoded library, based on 1,3,5-trichlorotriazine 263
- encoded library technology (ELT) 402, 414–416
- encoded self-assembling chemical libraries 266, 267
- endogenous ligand 161
- endothelin receptor antagonists (ETA) 237, 239
- energetics of binding. *see* target potency
- engineering 308
- enthalpic efficiency (EE) 372, 373
- enthalpic interactions, importance of 373, 374
- enthalpy 368
 - of binding 371
 - as a key decision tool in medicinal chemistry 371–373
- enthalpy–entropy compensation 390
- entropy 39, 372
 - driven binding 371
- ent-vorapaxar 556
- enzymatic activity 401
- enzyme assays 458
- epoxide hydrolase 166
 - inhibitors, soluble 498
- erythrocyte sialoglycoconjugates 661
- estradiol 229
- ETA. *see* endothelin receptor antagonists (ETA)
- ethyl ester prodrug 673
- ethylisopropyl amiloride (EIPA) 245
- ethyl urethane 562

- *ex vivo* platelet aggregation inhibition assay 562
- solubility issues with 563
- EU Openscreen consortium 314
- European Lead Factory 15, 315–317
- European Molecular Biology Laboratory (EMBL-EBI) 315
- European Strategy Forum on Research Infrastructure (ESFRI) 314
- europium chelate 599
- evolutionary algorithms (EAs) 439
- exosite binding theory 576

f

- factor Xa 386
- “failing quickly” concept 342
- fast follower approach 201, 202
 - omeprazole-based 203–210
 - rimonabant-based 210–214
 - salfanilamide-based 202, 203
- fast follower (FF) approaches 333
- FBDD. *see* fragment based drug discovery (FBDD)
- FBLG. *see* fragment-based lead generation (FBLG)
- FDA. *see* Food and Drug Administration (FDA)
- fenticonazole 228
- FFA. *see* free fatty acid (FFA)
- FieldStere 174
- filters application, in measuring/calculated properties 431, 432
- FIRE. *see* fragmentation intelligent recombination enumeration (FIRE)
- approach
- flavonoids, with oligopolysulfated moiety 246–249
- flexible multiparameter-based LG metrics 27
- flow chemistry 501
- fluconazole 228
- fluorescence intensity 70
- fluorescence polarization (FP)
 - measurements 284
- Fluorescent Imaging Plate Reader (FLIPRTM)
 - technology 293
- fluorescently labeled compounds 415
- Fluorescent resonance energy transfer (FRET) 116
- ortho*-fluoro derivative 704
- fluorophore photobleaching 70
- fluoroquinolone 755
- FOG. *see* frequency of group (FOG)
- fondaparinux 249
- Food and Drug Administration (FDA) 667
- formoterol 584
- fosinoprilat 161
- fpocket 56
- fragmentation and enumeration (FE) 748
- fragmentation enumeration method, workflow of 749
- fragmentation intelligent recombination enumeration (FIRE) approach 759
- fragment-based approaches 160
- fragment based drug discovery (FBDD) 8, 367, 747
 - strategies 226
- fragment-based lead generation (FBLG) 16, 20, 133, 184, 333, 402
- fragment-based ligandability screens 53
 - targets against 53
- fragment-based methods 133
- fragment-derived candidates 133
- fragment 7-FRAG 697, 700, 701
 - 2D depiction of binding modes of 701
- fragment growing 140–144
 - discovery of vemurafenib from a generic kinase-active fragment 141
 - from fragment to candidate: LY2811376 BACE inhibitor 142
 - isothiouraea BACE binder, evolution and optimization 144
- fragment libraries 135, 439
 - efficient sampling 133
 - screening 49, 50, 412
- fragment linking 144–147, 374–381
 - discovery of an LDHA inhibitor
 - by fragment linking at Ariad 148
 - by fragment linking at AstraZeneca 146
 - extensive medicinal chemistry to deliver a MMP-2 inhibitor 144
 - superposition of crystallographic structures 147
- fragment replacement 439
- fragments’ ability 135
- fragment screening 44
 - hit optimization 374–381
 - for ligandability assessment 50–54
- fragments, defined as 133
- free energy 392
- free fatty acid (FFA) 598
- frequency of group (FOG) 632
- Fsp3, comparison of 752
- FTrees fragment
 - space search in the GPR119 project 172
- functional assays 68, 70
- functional GABA-A agonist analogs 229
- furanose derivative 674
- fused diaza[3.3.0]cyclooctanes 111

g

GABA_A receptor 193
Galbulimima belgraveana 547
 Gartner's hype cycle 164
 gene knockout data 41
 generic structure 586
 genetic algorithm (GA) guided MPO 439
 genetic editing 63
 genetic expression analysis 16
 genome-wide expression analysis (GWAS) 16
 GFR. *see* human glomerular filtration rate
 ghrelin 637
 – agonist 15
 Gibbs free energy 367, 368
 Gibbs–Helmholtz equation 408
 GLIDE docking software 708
 Glide XP module 757
 glucagon-like peptide-1 (GLP-1) 277
 glucokinase activators
 – allosteric 115
 – templates for alignment studies 115
 glucuronidation 581, 585
 glucuronide metabolites 580
 glutamatergic excitotoxicity 515
 glycerol side chain 671
 GPCR. *see* G-protein-coupled receptor (GPCR)
 GPR81. *see* G-protein-coupled receptor 81 (GPR81)
 GPR119 agonists 172
 GPR119 compounds 173
 G-protein activation 551
 G-protein-coupled receptor (GPCR) 16, 38, 115, 116, 151, 152, 175, 290, 333, 443
 – β_2 -adrenoceptor (β_2 AR) 575
 – – agonists of 575
 – class B 41
 – crystal 22
 – crystal structures of 577
 – drug discovery 22
 – lead generation 22
 – novel A2AR antagonists, optimization of 152
 – pharmacology 22
 – signaling 22
 G-protein-coupled receptor 81 (GPR81) 598
 – adipose tissue 598
 – cAMP assay 630
 – endogenous ligands 598
 – – 3-hydroxy-butyrate 598
 – – 3-hydroxyoctanoate 598
 – – lactate 598
 – initial screening cascade 600
 – potency 622

G-protein-coupled transmembrane signaling 551
 G-protein-linked histamine receptor 516
 GRID analysis 163
 GTP γ S assay 519, 529
 guanidyl compound 163
 guinea pig model 581
 – bronchoprotection model 592
 – histamine-induced bronchoconstriction 589
 GWAS. *see* genome-wide expression analysis (GWAS)
 gyrase inhibition 755

h

haemagglutinin 675
 haemagglutinin–esterase fusion protein (HEF) 653
 H₃ affinity 537
 H₃ agonists 516
 – imetit 516
 – immepip impair cognitive function 516
 – R- α -methylhistamine 516
 halo-aromatic S1 group binder 389
 halogen atoms 386
 – interactions with π -systems 386
 halogen bonds 388
 H₃ blockers 529
 – pharmacophoric model 532, 534
 – synthesis with cyclobutoxy spacer 532
 H-bond acceptors 358
 H-bonding parameters
 – and conformational analysis in HtL 355
 H-bonding strengths 354
 HCA1. *see* hydroxycarboxylic acid receptor 1 (HCA1)
 HCASMC. *see* human coronary artery smooth muscle cells (HCASMC)
 HCV polymerases 15
 HCV protease 15
 HDAC inhibitors (HDACi's) 194, 196
 HE. *see* hit evaluation phase (HE)
 heat capacity 368, 370, 411
 heat maps 24
 heavy atom count (HAC) 337
 heavy halogen interaction 387
 HEF. *see* haemagglutinin–esterase fusion protein (HEF)
 α -helical structures 260
 heptapeptide 164
 hERG 332, 454
 – to free $C_{\max}$ ratio plotted vs. arbitrary syntheses 480
 – hit selection triage cascade 338

- -induced cardiac side effects 27
- inhibition 24, 29, 454
- – of ion channel 438, 454, 528, 537
- liabilities of compounds 25, 27
- Nav pIC₅₀ vs. hERG pIC₅₀ 455
- safety 577
- selectivity 531, 537
- *in vitro* potency at target of interest 340
- heteroaromatic bioisostere 335
- heteroaryl-NH-aryl motif 340
- heteroatoms 388
- heterocyclic ketone moiety 693
- hexamethylene amiloride (HMA) 245, 246
- H₃ heterozygous knockout mice 516
- H1/H3 hypothetical molecule 700, 702
- hH₃R agonist 518
- high agonist intrinsic activity (IA) 576
- high-content screening 293
- highly polar drug 667
- Diskhaler technology 668
- oral inhalation 667
- high-quality candidate 25
- high-quality leads 18
- compounds screening 19, 20
- to generate, compounds to screen 18
- three clusters 18
- three singletons 18
- high-throughput screening (HTS) 8, 9, 13, 20, 23, 95, 159, 184, 221, 331, 336, 372, 401, 451, 554, 575, 597, 747
- -based approach 43
- campaign 159
- clustering 615
- compound set enrichment (CSE) 608
- compound testing 606
- detection assay 348
- hit evaluation phase (HE) 597
- hit rate 606
- libraries 22
- limitations 44
- nearest neighbours 618
- outcome 20
- robotic screening methodology 38, 43
- single-concentration counterscreen 614
- workflow 335, 693
- himbacine 547
- analogs 548, 561
- derivatives 548
- himbacine-derived PAR-1 antagonist 556
- hit 548
- himbacine-derived thrombin receptor antagonists 553
- discovery of vorapaxar (SCH 530348) 564
- – clinical studies of 566
- lead generation 554
- – aryl himbacine leads, generation of 561
- – first-generation thrombin receptor antagonists 557
- – nor-seco himbacine lead, identification of 563
- – second-generation leads 562
- – structure–activity relationship studies 556
- – *in vivo* metabolism of himbacine derivatives 559
- lead identification 553
- ent*-himbacine enantiomer 548
- himbacine, total synthesis of 553
- [³H], intravenous administration of 561
- H₃ inverse agonist clinical candidate 539
- His residue 687
- histamine 516, 592
- – containing neurons 516
- histaminergic system, modulation of 516
- histone acetyltransferases (HATs) inhibitors 193
- histone deacetylases 193
- hit assessment 622
- lipophilicity efficiency assessment 622
- secondary pharmacology assessment 626
- hit compound 498
- hit evaluation phase (HE) 597
- binding kinetics 621
- – curve shifts, influence on 621
- – pan-assay interference (PAINS) 621
- biological effect assay 634
- curves 618
- dose–response behavior 618
- efficacy 618
- enzyme concentration 620
- hit assessment 622
- – lipophilicity efficiency assessment 622
- – secondary pharmacology assessment 626
- hit expansion 630
- potency 618
- potency data 618
- secondary screening cascade 630
- steep curve behavior 619
- stoichiometry complexes 620
- hit generation 747, 754
- by chemogenomics approaches 174–177
- by rational library design 165–167
- by scaffold replacement technologies 173, 174
- success rates 52
- by virtual screening 167–169

- – ligand-based VS in nonenumerated virtual chemical spaces 171–173
 - – structure-based VS in enumerated molecules 170, 171
 - hit identification 517
 - hit optimization 139, 140
 - hit-to-lead (H2L) 331, 451
 - campaigns 756
 - of natural product enopeptins 350
 - progress in β -secretase project 404
 - Hit validation 137, 138
 - HIV protease inhibitors 159, 161, 163, 371. *see also* saquinavir
 - enthalpy of binding 371
 - entropy changes 371
 - Gibbs free energy 371
 - H2L. *see* hit-to-lead
 - H₃ ligands 517, 518
 - histamine 517
 - immethridine 517
 - methimepip 517
 - HLM. *see* human liver microsomal stability (HLM)
 - [³H], metabolite profiling of 559
 - HMG-CoA reductase inhibitors 372
 - enthalpy of binding 371
 - entropy changes 371
 - Gibbs free energy 371
 - [³H]-N^α-methylhistamine displacement assay 517
 - homologization 441
 - homology model 586
 - bovine rhodopsin structure 586
 - Horner–Wadsworth–Emmons reaction 554
 - HPLC biogram fractionation experiments 361
 - H₃R as heteroreceptor 517
 - H₃ receptor, cloning of 516
 - H₃R modulators 518
 - HSA. *see* human serum albumin
 - 5-HT_{2B} serotonin receptor 443
 - HtL and structure-based drug design 356
 - HtL campaign 348
 - goal of 348
 - HtL from a phenotypic screening hit, leading to daclatasvir 362
 - HtL library 358
 - HtL phase 359, 360
 - strategies and workflow 332
 - HTS. *see* high-throughput screening (HTS)
 - human coronary artery smooth muscle cells (HCASMC) 565
 - human dose predictions
 - eD2M values 471
 - human “druggable genome” 40
 - human ether-à-go-go-related gene. *see* hERG
 - human glomerular filtration rate (GFR) 476
 - human influenza 651
 - glycoproteins 652
 - influenza B viruses 652
 - influenza C viruses 652
 - inhaled administration 652
 - therapeutic strategies 652
 - vaccination 652
 - viral RNA polymerase 652
 - human liver hepatocyte 560
 - human liver microsomal stability (HLM) 632
 - human proteome 42
 - human serum 660
 - human serum albumin (HSA) 466
 - human sialidases 666
 - hydrochlorothiazide 237
 - hydrogen bonds 40, 133, 368, 668
 - donors 368, 583
 - hydrophilic interactions 352
 - hydrophobic groups, bulky 497
 - hydrophobic interaction 199
 - hydrophobicity 351, 497
 - role, and HtL 351, 352
 - hydrophobic properties 369
 - hydrophobic surface 40
 - hydroxamate-containing HDACi's trichostatin A (TSA) 194
 - hydroxybenzoic acid 639
 - 4-hydroxybenzothiazolone 580
 - hydroxycarboxylic acid receptor 1 (HCA1) 598
 - 7 α -hydroxy derivatives 559
 - 7 β -hydroxy derivatives 559
 - 5-hydroxy-4*H*-benzo[1,4]oxazin-3-one 581
 - α -hydroxylated metabolite 564
 - hydroxyl group 663, 669, 670
 - 3-hydroxy-3-methylglutaryl coenzyme A 371
 - 5-hydroxy-pyrazole-3-carboxylic acids 702
 - 8-hydroxyquinolone catechol 578
- i*
- IAM. *see* immobilized artificial membrane
 - ibipinabant 214
 - ICH. *see* intracranial hemorrhage (ICH)
 - IC₅₀ values 27
 - ideal lead generation strategy 21
 - ileal myenteric plexus assay 529
 - Imatinib 115
 - IMDA, diastereoselectivity of 555, 556
 - IMDA precursor 556
 - imidazole-like α -2 AR agonists 518

- imidazopyridines 209, 603
 - -based PPI 209
 - imipramine 229
 - immobilization process 405
 - immobilized artificial membrane (IAM) 466
 - indacaterol 579, 585
 - discovery of 579
 - induced pluripotent stem cells (iPSC) 16, 290
 - influenza virus sialidase 662, 666
 - inhibitors 675
 - susceptibility 675
 - influenza virus sialidase inhibitors,
 - development of 658
 - monitoring resistance to influenza virus sialidase inhibitors 675
 - noncarbohydrate scaffolds, sialidase inhibitor development on 671
 - – oseltamivir development 671
 - – peramivir development 673
 - sialidase inhibitor drug 659
 - – influenza virus sialidase, selection 666
 - – inhibitor binding mode, X-ray crystallographic of 665
 - – polar drug administration, mode of 667
 - – prodrugs and multivalency 668
 - – structure-based inhibitor design 662
 - – template selection 659
 - – virus replication, efficacy against 667
 - InhA, cocrystal structure of 757
 - inhaled therapy 577
 - DMPK of 577
 - inhibition in solution assay (ISA) 405
 - Innovative Medicines Initiative (IMI) 315
 - in silico* methods 42
 - integrin 415
 - intellectual property 309
 - interfering RNA 63
 - interstitial waters, and usefulness 381
 - intestinal epithelial cells 668
 - intracellular Ca^{2+} signaling 336
 - intracranial hemorrhage (ICH) 569
 - intramuscular administration 675
 - intravenous administration 675
 - intrinsic chemical tractability 39
 - in vitro* target-based assays 310
 - in vivo* proof of concept 711
 - ion channels 116
 - ion-pairing potential 40
 - isocytosine hit 404
 - isoindolinone ring 499
 - isosterism 230
 - isothermal titration calorimetry (ITC) 21, 407–411
 - application in lead generation 410, 411
 - applying Gibbs–Helmholtz equation 408
 - binding mode of melagatran 410
 - challenge in thermodynamic data interpretation 409
 - changes in solvent organization 410
 - displacement 408
 - instrument 408
 - observed binding enthalpy 409
 - ITC. *see* isothermal titration calorimetry (ITC)
 - Itraconazole 228
- k**
- kallikrein 691
 - ketokonazole 228
 - kinase inhibitors 463
 - kinases 15, 16, 114, 497
 - DYRK 498
 - – binding mode/selectivity of 498
 - high-throughput 115
 - strategy of scaffold swapping 115
 - TNIK 504
 - Wee-1 504
 - kinetic analysis 407
 - kinetic isotope effect 164
 - kinetic properties 367
 - kininogen 691
 - “knockdown” effect 331
 - “knock-in” (KI) or “knockout” (KO) genes 66
 - Kolmogorov–Smirnov test (KS) 608
 - 10 k selection 602
 - checklist 603
 - outcome 605
 - kyurenine aminotransferase
 - identifying bioactive impurity, and subsequent optimization 360
 - for schizophrenia 359
- l**
- LABA. *see* long-acting β_2 AR agonist
 - lactacystine 690
 - β -lactamase inhibitors 42
 - lactams 532
 - lactate dehydrogenase A (LDHA) 51
 - inhibitors 51
 - lactone carbonyl group 554
 - β -lactone omuralide 690
 - lactone ring 556
 - laninamivir octanoate 670
 - lansoprazole 42, 208
 - LE. *see* ligand efficiency
 - lead compound 675
 - lead discovery 692

- high-throughput screening and data analysis 692
- hit series, evaluation of 693
 - covalent inhibitor series 693
 - malonamide series 697
 - pyrazolone hit series 698
- novel lead structure 699
- 9b bound to CatA, crystal structure of 705
- lead generation (LG) 14, 451, 521, 747, 748
 - campaign 17, 24
 - delivered successfully 27
 - design, make, test, and analyze (DMTA) cycle 489
 - drug discovery programs 577
 - evaluation 754
 - preliminary experimental 755
 - *in silico* 755
 - virtual screening using enzyme–ligand docking 756
- evolution of 20
- medicinal chemist 18
- medicinal chemistry 577
- paradigm 17
- phase, overview of 536
- portfolio management techniques 21
- principle 748
- program 522
 - H₃ blockers, discovery of 523
- oxazoline bioisosteres, identification of 522, 532
- oxazoline ring, substitution exploration on 522, 523
- propoxy linker, rigidification of 522, 531
- three-pronged chemical strategy for 523
- projects failure 17
- projects, ingredients 20
- puzzle 17
- research methodology 748
- fragmentation 749
 - intelligent recombination and enumeration 754
- strategy 22
- success rates 20
- selecting target defines 21
- technologies 18
- lead identification 117
- lead-like space 107
- lead optimization (LO) 6, 13, 14, 451, 492, 703, 705
 - campaign 348
 - and candidate selection 537
 - phases 331
- lead quality 467
 - bioavailability 467
 - dose to man as a measure of 467
 - drug failure, reasons for 467
 - early-stage 467
 - human pharmacokinetics 468
 - late-stage 467
 - structure–property relationships 468
- Leeson, Paul 9
- lenalidomide 234
- leucine residue 694
- Lewis acid 109, 386, 388
- Lewis basic electrostatic potentials 388
- Lewis basic groups 387
- LFA-1 antagonist 416
- LG. *see* lead generation (LG)
- liabilities 25
 - improvements 24, 25
- library design 102
 - enumeration and filtering 104–106
 - four-dimensional (and higher) libraries 104, 105
 - layout 106
 - library manufacture 106
 - purification 107
 - number of dimensions 103
 - one-dimensional libraries 103
 - three-dimensional libraries 103, 104
 - two-dimensional libraries 103, 104
- ligand 497
 - efficiency of 497
 - lipophilicity efficiency of 497
- ligandability 7, 38, 39, 40, 41, 42, 43
- ligandable targets, characteristics 39
- ligand-based methods 428
- ligand-based pharmacophores 358
- ligand-based screening techniques 756
- ligand efficiency (LE) 7, 372, 458, 463
 - and other metrics 138, 139
- ligand–protein complex 135
- ligand–protein interactions 40, 429
- ligands, maximal affinity of 41
- Lilly's open innovation drug discovery 310–312
- Lilly's PD2 platform 311
- Lindlar reduction 554
- Lipinski, Chris 4
- Lipinski-like oral space 15
- Lipinski's rule of five 111
- lipophilic compounds 458
- lipophilic efficiency 7
- lipophilic exploration 498
- lipophilic groups 497
- lipophilic hits 498

- lipophilic interactions 7, 369
- lipophilicity 4, 5, 8, 13, 24, 353, 359, 386, 456, 580, 673
 - design concept to explore effect and chemical scaffold 580
 - duration of action with 580
 - experimental description of 458
 - increases in 589
 - lipophilic ligand efficiency 458
- lipophilic ligand efficiency (LLE) 458, 518, 697
- liver
 - hepatocytes 470
 - microsomal protein 470
- LLE. *see* lipophilic ligand efficiency (LLE)
- LO. *see* lead optimization (LO)
- local drug administration techniques 27
- logD 24
- logistics 308
- logP 24
- long-acting β_2 AR agonist (LABA) 575, 578
 - formoterol 575
 - salmeterol 575
- Lou Gehrig's disease 190
- lovastatin 194, 196
- low-cost medicines 718
- low oxygen recovery assay (LORA)
 - conditions 732
- lozapine succinate 228
- luciferase 70
- luciferin 70
- Luc inhibitors 70
- lysosomal carboxypeptidase 689
- m**
- MACCS fingerprints 335
- macrolide-like compounds 111
- macromolecules 41
- "magic methyl" phenomenon 349
- malaria 717
 - apicomplexan parasite 719
 - asexual blood-stage phenotypic screening 724, 725
 - eradication, screening for 729
 - lead generation strategy 719
 - life cycle of parasite 720
 - medicines for 719
 - *Plasmodium falciparum* 719
 - *Plasmodium knowlesi* 719
 - *Plasmodium malariae* 719
 - *Plasmodium ovale* 719
 - *Plasmodium vivax* 719
 - risk of infection 719
 - SERCaP or single exposure radical cure and 719
 - target-based approaches 723, 724
 - target candidate profiles (TCPs) 720–722
 - whole-cell screening: results 725, 726
- malonamide series
 - electron density observed on 698
 - fragmentation of 698
- malonic acid 697
- mammalian proteases 163
- management 309, 310
- MAPpod 56
- marine natural product 580
 - library expansion of 580
- marketed antimalarial chemotype, optimization of 723
- MARKUSH formula 230
- mass balance assay 562
- mass spectrometry (MS) 49
 - approaches 402, 412–414
- matched molecular pair analyses (MMPA) 503
- matched molecular pair (MMP) analysis 441
- matched pair analysis 348–351
- mathematic exercise 18
- maximum common substructure (MCS) 608
- MCS. *see* maximum common substructure (MCS)
- MDCK-MDR1 permeability 24
- MDS. *see* multidimensional scaling
- mean physchem property values 8
- medicinal chemistry 3, 6, 64, 454, 497
 - strategy 212
- Medicines for Malaria Venture (MMV) 317–319
- medium-throughput screening (MTS) 20, 95
- melatonin 187
 - designs of novel ligands 186
- membrane-bound receptors 22
- metabolic stability 24, 25
- metabolic susceptibility 580
- metabolism 401
 - -induced toxicity 25
- metabotropic glutamate receptor (mGluR2)
 - allosteric modulator, positive 499
- meta*-Cl derivative 705
- meta*-fluoro analogs 704
- metal ions 40
- Met98, H-bonding interaction with 758
- methotrexate 226
- methylation 237
- N*-methyl-D-aspartate antagonist 346
- R*- α -methylhistamine (RAMH) 516
- (*R*)- α -methylhistamine 519

- 2-methylindoline compounds 442
 (2*R*)-methylpyrrolidine enantiomer 524
 metronidazole 324
 mexiletine 243, 244
 MI. *see* myocardial infarction (MI)
 Michael acceptors 361
 miconazole 228
 micro-ARCS 184
 microdialysis 519
 microfluidic mobility shift assay 692
 microkinetic theory 585
 microscale thermophoresis (MST) 49, 417, 418
 midazolam 228
 milveterol 583
 – discovery of 583
 minaprine 229, 237
 minaprine analogs 236
 mitochondrial permeability transition (MPT) 192
 mitochondrial toxicity 632
 mitogenesis 551
 MMPA. *see* matched molecular pair analyses
 MMV. *see* Medicines for Malaria Venture (MMV)
 MMV Pathogen Box 318
 mode of administration 464
 MOE scaffold 174
 molecular complexity 7, 43, 44
 molecular interactions 368
 – thermodynamics of 369, 370
 Molecular Libraries Probe Production Centers Network (MLPCN) 312
 Molecular Libraries Screening Centers Network (MLSCN) 312
 Molecular Libraries Small Molecule Repository (MLSMR) 312
 molecular library program 312–314
 molecular mechanism of action (MMoA) 63
 – annotated sets of small molecule probes 64
 – deconvolution 68
 – elucidation 64
 molecular obesity 4
 molecular recognition 367
 molecular weight 24, 27, 499
 Molecule–protein interactions 120
 monobasic oxazoles 527
 morphine 232
 – analogs 232
 morpholine–amide derivative 539
 MoSELECT, library selection method 445
 MPO. *see* multiparameter optimization
 MS-based proteomics 22
 MST. *see* microscale thermophoresis (MST)
 Mtb. *see* *Mycobacterium tuberculosis*
 multicomponent reactions 107, 108
 multicriteria decision making (MCDM) 430
 multidimensional optimization (MDO) 430
 multidimensional scaling (MDS) 504
 – application of to visualize diversity of chemical space from compounds of nine different NaV1.7 patent 507
 multidrug-resistant (MDR) tuberculosis 730
 multienzyme complex 688
 multiobjective optimization (MOOP) 430
 multiparameter exploration (MPE) 332
 multiparameter lead optimization 25
 multiparameter optimization (MPO) 24, 25, 427, 430, 467
 multiparameter score 444
 multiple ligands 224
 Multitargeted drug discovery projects 115
 multivalency 668
 multivariable data sets 504
 muscarinic M₃ antagonists 576
 muscarinic receptor 548
 mutation 66
Mycobacterium tuberculosis 311, 412, 729, 755
 myocardial infarction (MI) 547, 549, 568
- n**
 native-state electrospray ionization (ESI) MS 49
 natriuresis 711
 natural killer (NK) cell 654
 natural products 118, 547, 747
 – utilization, for lead generation 118
 NCE. *see* new chemical entities
 nearest neighbours (NN) 602
 – analysis 333
 – searching 336
 neglected tropical diseases (NTDs) 717. *See also* malaria
 – drug development for 718
 – hit generation strategies for 718
 – hit identification strategies 722, 723
 – – clinically validated historic targets 722
 – – DHFR and DHODH 722
 – infectious bacterial diseases 717
 – infectious parasitic diseases 717
 – infectious viral diseases 717
 – lead generation strategies for 718
 – leishmaniasis 717
 – lymphatic filariasis 717
 – onchocerciasis 717
 – repositioning of clinical candidates, developed for other indications 726, 727

- schistosomiasis 717
 - NEP. *see* neutral endopeptidase (NEP)
 - NET/DAT HtL strategies 339
 - 5-(*N*-ethyl-*N*-isopropyl) amiloride (EIPA) 246
 - neuraminidase
 - binding pocket 163
 - inhibitors 161, 162
 - neurodegenerative disorder 515
 - neuropsychiatric symptoms 515
 - neutral compound 472
 - neutral endopeptidase (NEP) 691, 705
 - new chemical entities (NCEs) 183, 470, 717
 - new chemical modalities 15
 - new molecular entities (NME) 64
 - new screening compounds, generation of 99–102
 - niching 444
 - NIH Clinical Collection (NCC) 312
 - nitrite-based cysteine protease inhibitors 42
 - NK. *see* natural killer (NK) cell
 - NMDA antagonist 515
 - NMDA NR2B screening cascade 347
 - NMR spectroscopy 44, 47
 - NN. *see* nearest neighbours (NN)
 - nonbiological host–guest complexes 390
 - noncarbohydrate scaffolds 671
 - nonclassical hydrogen bonds 386
 - noncovalent interaction 386
 - nondruglike properties 24
 - nonhuman cells 68
 - nonhuman gene products 41
 - nonnatural phosphor-peptide binders, of Grb2 SH2 domain 372
 - nonpeptidic derived small-molecule inhibitors 14
 - nonprotein entities 41
 - nonreplicating persistent (NRP) 755
 - nonsteroidal anti-inflammatory drugs (NSAIDs) 37, 201
 - nor-seco himbacine derivatives 563
 - ring system 563
 - synthesis of 564
 - NovaTM module 440
 - NRP. *see* nonreplicating persistent (NRP)
 - NRP-active anti-TB compounds 755
 - NS5A inhibitors 361
 - NTDs. *see* neglected tropical diseases (NTD)
 - nuclear hormone receptors 38
 - nuclear magnetic resonance (NMR) 21
 - spectroscopy 402–404
 - nucleic acids 41
 - nucleosides 16
 - nucleotides 16
- o**
- off-patent drugs 226
 - OIDD agreements 311
 - “old drugs” 226
 - categories 226
 - omeprazole 42, 206
 - omeprazole-based fast follower approaches 203–210, 209
 - omeprazole-based PPIs 209
 - on-bead screening 120, 121
 - challenges 120
 - onebead- one-compound (OBOC) libraries 120
 - on/off/KD map 407
 - Open Innovation Drug Discovery (OIDD) platform 310
 - Open lab foundation 321, 322
 - open-minded chemistry 20
 - Open Source Drug Discovery (OSDD) 323
 - Open Source Malaria (OSM) project 320
 - optical biosensors 404
 - optical waveguide grating (OWG) 404, 405, 406
 - optimization 230, 444
 - campaign 359
 - cycles 540
 - oral absorption 586
 - Lipinski’s guidelines for 586
 - oral administration 673
 - oral bioavailability 39
 - organic synthesis 501
 - organoids 67
 - organometallic ligands 40
 - oseltamivir 675
 - oseltamivir carboxylate 674
 - OWG. *see* optical waveguide grating (OWG)
 - oxazoline 529
 - oxiconazole 228
 - oxocarbenium ion 672
 - intermediate 671
 - oxyanion hole 694, 697
- p**
- PAD. *see* peripheral arterial disease (PAD)
 - pantoprazole 207
 - papain-like protease/deubiquitinase 503
 - small-molecule inhibitor of 503
 - parallel synthesis approach 501, 585
 - parentfluoroquinolone 755
 - pareto ligand designer 440
 - pareto optimization 435, 436
 - Parkinson’s disease 152, 190, 516
 - PARs. *see* protease-activated receptors (PARs)

- patients 575
 - groups 718
 - suboptimal bronchodilation effect on 575
- PCA. *see* principal component analysis
- PCI. *see* percutaneous coronary intervention (PCI)
- PCN. *see* pregnenolone 16 α -carbonitrile (PCN)
- PDPs. *see* product development partnerships
- pentynoic acid benzyl ester 554
- pepducins 641, 642
 - *N*-terminally palmitylated peptides 642
 - structure 642
- peptide 63
- peptide amide linker (PAL) resin 282
- peptide ligands 367
- peptide stability assay 288
- peptidomimetic thrombin receptor (PAR-1) antagonist RWJ-58 259 553
- percutaneous coronary intervention (PCI) 567
- peripheral arterial disease (PAD) 568, 569
- perivascular administration 553
- perturbation 40
- P-glycoprotein 1 mediated efflux 14
- pharmaceutical industry 502, 717, 747
 - reality of 502
- pharmacodynamics (PD) 27, 37, 39, 452
- pharmacokinetic (PK) 39, 452, 593
- pharmacokinetics 468, 562
 - model for 469
 - – new chemical entities (NCE) 470
 - – QSAR model 471
 - – regression correction 470
- pharmacokinetics (PK) 27
- pharmacophore 429
 - dibasic 589
- pharmacophores 506, 756
 - methods 429
- pharmacophoric linker replacement tool 439
- phenol 579
- phenotypic assay
 - assay technologies and perturbation measured in 69
- phenotypic assays 292, 458
 - cell-viability assay 292, 293
 - fluorescent imaging plate reader technology 293
 - high-content screening 293
- phenotypic-based drug discovery approaches 63
- Phenotypic Drug Discovery Initiative 310
- phenotypic screen 17, 22, 260, 289–290, 291
 - assay design 291
 - campaign 64
 - hit selection and secondary assay 291
 - identify “druggable” phenotype and type of readout 291
 - *in vitro* screening 293
 - – classic phenotypic screening 293, 294
 - – comparison of immortalized, primary, and iPSCs for phenotypic screening 294
 - – disease-relevant phenotypes developed by patient-derived iPS cells 295
 - – high-content cytotoxicity screening by iPSC-derived hepatocytes 296, 297
 - – patient-derived stem cell in drug discovery 294, 295
- phenyl amino-oxazolines 525
- phenyllactam, *in vitro* properties of 535
- phenyloxazoles 524
- phenyloxazolines, structures and activities of 519
- phenyl ring 561
- p53/(H/M) DM2 inhibitors 344
- phosphatases 17
- phosphodiesterases (PDE) 231
- phospholipase D2 inhibitor (PLD2) 349
- phospholipidosis 632
- phospholipids 576
- physical properties 335
- physicochemical 452
 - properties 7, 14
- physiological pH 579
- piperazine 699
- piperidine 699
- PK. *see* pharmacokinetic
- plasma 475
 - drug in 475
- plasma protein binding (PPB) 453, 632
- plasminogen activation system (PAS) 245
- Plasmodium falciparum* 239, 317
- platelet activation mechanism 558
- platelet aggregation 551
 - inhibition assay model 557, 559
- platelet-rich plasma (PRP) 565
- platinum oxide 554
- p53/MDM2 interaction 117
 - inhibitors 117
- polar amines 539
 - hydroxypiperidine 539
- morpholine 539
- piperazines 539
- polar functionalities 40
- polar groups 212, 498
 - compatibility of 498
- polar interactions 49, 368

- polar surface area (PSA) 464, 503
- polypharmacology 224, 225
 - improve therapeutic efficacy and 225
 - unintended 225
- polysulfated flavonosides 249, 250
- polysulfated oligoflavonoids 249
- pomalidomide 234
- poor-quality compounds 9
- positional scanning synthetic combinatorial libraries (PS-SCL) 121
- positive proof of concept (PoC) 65
- positron emission tomography (PET) 199, 200
- posterior hypothalamic neurons 515
- potency 25
- potential chemical advantages 15
- potential disease-associated gene products 41
- potential drug targets 39, 41
- potent MAO-A inhibitor 227
- PPB. *see* plasma protein binding (PPB)
- pregnenolone 16 α -carbonitrile (PCN) 559
- primary activity assays 453
- primary urethane 565
- principal component analysis (PCA) 504
- probabilistic scoring 432–435
- probe H-bond donors and acceptors 353
- probe H-bond topology and electronics 353
- prodrugs 441, 668
 - approach 705
- product development partnerships (PDPs) 318, 717
 - Drugs for Neglected Diseases Initiative (DNDi) 717
 - Global Alliance for TB Drug Development (GATB) 717
 - Medicines for Malaria Venture (MMV) 717
- profiling distribution, metabolism, and pharmacokinetics (DMPK) 454
 - design rules for 464
 - drug efficiency index (DEI) 465
 - immobilized artificial membrane (IAM) 466
 - other design rules for 465
 - polar surface area (PSA) 464
 - protein binding 466
 - rules for 464
 - total polar surface area (TPSA) 464
 - Veber rules 464
- property prediction 427
 - software commonly used to evaluate 428
- property profiles
 - and score plots 438
- property-related restrictions 40
- propoxy amides, brain receptor occupancies of 542
- propoxy analogs 539
- propoxy linker, replacement of 531
- 3-propoxy linker, rigidification of 534
- propranolol 235, 237
- proprietary screening methods 23
- protease-activated receptor-1 (PAR-1) 547–558, 560–567, 569
- protease-activated receptors (PARs) 549
- proteasome 690
- protein 63
 - binding 21, 466
 - consumption 49
 - cryptic binding pockets 40
 - crystallography 18
- Protein Data Bank (PDB) 357
- protein–DNA interactions 284
- protein gene products 41
- protein kinases 38, 41, 114
- protein preparation 429
- protein–protein interactions (PPIs) 15, 17, 41, 42, 117, 147–151, 259, 343, 415
 - antagonists, statistical analysis 117
 - discovery of ABT-263 by fragment linking and extensive medicinal chemistry 149
 - fragment growing to discover MCL-1 inhibitors
 - – at AbbVie 150
 - fragment merging to discover MCL-1 inhibitors
 - – at Vanderbilt University 149
 - superposition MCL-1 inhibitors 151
- protein–protein “interactome” 41
- proteins 41
- proteolysis 284
- proteolytic cleavage 15
- proton pump inhibitors 42
- PRP. *see* platelet-rich plasma (PRP)
- PSA. *see* polar surface area
- pseudo-irreversible inhibitors 42
- Psychoactive Drug Screening Program (PDSP) database 222
- PubChem database 222
- public–private partnerships 307
- P2Y₁₂ antagonist 569
- pyrazinamide (PZA) 754, 755
- pyrazoline ring 213
- pyrazolone 707
- pyrazolone hit series 698
 - affinity of 699
 - bound molecule on CatA surface 699
 - cocrystal structure of 699
 - potential binding mode of 698
- pyrazoloquinoline derivative 554

pyrexia 667
 pyridine 350
 pyridoxal 5'-phosphate 360
 pyrrolicarboxamides 757
 – binding mode of 757
 pyrrolidinones 406
 PZA. *see* pyrazinamide (PZA)

q

quantitative estimate of drug-likeness (QED) 4
 quercetin 3,3',40',7-O-tetrasulfate 249
 quinine 724
 quinoline 350
 quinolone, docking of 188

r

rabeprazole 208
 racemates
 – synthesis of 502
 – test of 502
 racemic compound 548
 racemic himbacine derivative 554
 radioligand binding assay 558
 ramelteon 187
 RAMH. *see* R- α -methylhistamine (RAMH)
 random-based HTS approach 159
 random HTS screen 23
 rat
 – cortex homogenate, *ex vivo* binding on 531
 – dose enzyme induction study in 560
 – hepatocyte 560
 rational design approach 710
 rat restenosis model 553
 (R)-3-butyn-2-ol 554
 RDE. *see* receptor destroying enzyme (RDE)
 real-time polymerase chain reaction (PCR)
 machine 49
 receptor destroying enzyme (RDE) 655
 receptor kinetics 576
 receptor–ligand interaction 195
 ReCore 174
 reduction in solubility/permeability 577
 renal proximal tubular cells 689
 renin–angiotensin system 692
 reporter gene assays (RGAs) 70
 rescue receptor 551
 research-based sectors 307
 resonant waveguide grating (RWG) 49
 respiratory tract 575
 right-sizing 24
 rimonabant 213
 rimonabant-based CB₁R antagonists
 – enhancing polarity 212

rimonabant-based fast follower approach 210
 rimonabant-based PPIs 212
 – introduction of polar groups 212
 risk sharing 308, 309
 RivaroxabanTM 388, 390
 RO3. *see* rule-of-three
 Rockefeller Foundation 717
 rule-of-three (RO3) 464
 3-O-rutinosides 249
 7-O-rutinosides 249

s

safety 225
 saligenin head group 583
 saliva 660
 salmeterol 576, 579, 583
 – lipophilic 4-phenylbutoxyhexyl group
 of 576
 – major metabolic pathway for 587
 salosyl cation 162
 salt bridges 584
 sampling of conformational preferences
 important for HTL library design 358
 Sanofi compound 692
 saquinavir 161, 163, 164
 SAR. *see* structure–activity relationship (SAR)
 SARS virus
 – replication of 503
 SBDD. *see* structure-based drug design
 scaffold hopping 439
 Schiff base 360
 schizophrenia 516
 scientists against malaria 322, 323
 scopolamine-induced cognitive deficits 516
 scoring profile 436
 – for selection of compounds 436
 screening cascade 599
 – selection criteria 599
 screening methods 16, 135–137
 screening of existing collections 96
 – high-throughput screening 96–98
 – medium-throughput screening 98, 99
 sEH inhibitors 160
 selective COX2 inhibitors 42
 selective optimization of side activities
 (SOSA) 16, 602, 748
 – approach 222
 – patentability and interference risk of 230
 – SOSA approach 224
 – – and analog design 227–230
 – – steps 224
 selective SSTR5 hits 160
 sequence homology 516

- serendipitous discoveries 747
- serotonin uptake (SERT) 338
- serum stability 39
- setraconazole 228
- SFLLRN, peptide sequences 551
- S1 group binding groups
 - as a function of rigidity of linking group 389
- S1 group interacting with Tyr-228 389
- [³⁵S]GTPγS assay 518, 520
- β sheets 687
- sialic acid 162, 163
 - -based receptors 675
- sialidases 161
 - action, proposed mechanism 657
 - inhibitors 675
- sialoglycoconjugate receptors 653
- Sibnadet 592
- signal-to-noise ratio 284
- sildenafil 226, 232
- single-concentration counterscreen 614
 - counterscreen data 615
 - efficiency index 615
- single-digit nanomolar compound 152
- single-dose therapeutic 670
- single-gene drug targets 38
- single photon emission computed tomography (SPECT) ligands 200
- singletons 618
- SIRT1–native peptide complex 401
- SIRT1–TAMRA–peptide complex 401
- small interfering RNA (siRNA) 16
- small-molecule binding pockets 43
- small-molecule chemical libraries 183
- small-molecule interaction 40
- small-molecule ligands 15
- small molecule microarrays (SMMs) 120
- small-molecule target identification techniques 75
 - affinity chemical proteomics 81–84
 - biochemical profiling 77, 78
 - chemical genetics 79, 80
 - *in silico* target deconvolution 75–77
 - subcellular localization 79
 - target corroboration 84–86
 - target deconvolution correlational tools 78, 79
- smooth muscle cell proliferation 553
- SMURF+, multiparameter risk function 28–30
 - application of 29, 30
- S_{NAR} reaction 754
- sodium channel inhibitors 505
- software 308
 - ROCS 172
 - used to evaluate similarity/complementarity and, by analogy, activity 428
- solid-phase peptide synthesis 120
- solubility coefficients 341
- solubility improvements 341
- soluble epoxide hydrolase (sEH)
 - inhibitors 160, 165
- solvation/desolvation effects 368
- somatostatin 176
- somatostatin receptors subtypes (SSTR1, SSTR2, SSTR3, and SSTR4) 177
- SOSA. *see* selective optimization of side activities (SOSA)
- sp³C atoms, fraction of 752
- speed 308
- split–mix synthesis 120
- S3 pocket binding group, and short halogen bond 387
- Src SH2 domain screening 371
- standard hit identification process 224
- stapled peptide 260, 276
 - affinity evaluation and α-helix content correlation 284
 - fluorescence polarization assay 284, 285
 - stapled peptide affinity and α-helix content correlation 285, 286
 - surface plasmon resonance binding assays 284
 - design 280–282
 - β-catenin armadillo domain 281
 - β-catenin/aStAx-35 complex 281
 - overview 276–278
 - permeability 286–288
 - solution α-helix conversion measurement 283
 - structure 278–280
 - ruthenium-catalyzed ring closing metathesis 279
 - stereo combinations with two chiral unnatural amino acids 279
 - synthesis 282
 - *N*-Fmoc-protected olefin substituted alanine 282
- stapled peptide technology 260
- StarDropTM 440
- statistical molecular design 358, 359
- stereochemistry 502
- steroid budesonide 575
- streptavidin 40
- structural analogs
 - of classical bioisosteric replacement of antipsychotic drugs 238
 - with different biological activity 229

- structural changes
 - lead to big binding mode changes 392
 - structural genomics programs 42
 - structure-activity relationship (SAR) 13, 23, 63, 183, 230, 556, 582, 597
 - analysis, of rimonabant-based series compounds 211
 - exploration 499, 518
 - by NMR 184
 - optimization 63
 - structure-based drug design (SBDD) 578
 - structure-based library design 115
 - structure-driven approaches 109
 - 3D skeletons 111
 - macrocycles 111, 112
 - natural product-inspired compounds 110, 111
 - privileged structures 110–112
 - toward bioactivity 110
 - toward uncharted territory 112–114
 - structure-kinetic relationships 406
 - structure-property relationships (SPRs) 468, 597
 - suberoylanilide hydroxamic acid (SAHA) 194
 - subset/“validation set” screening 43, 44
 - substrate design strategy 164
 - success rates 38
 - sulbactam 42
 - sulconazole 228
 - sulfanilamide 202, 235
 - -based fast follower approaches 202
 - sulfated flavonoids 247
 - sulfathiazole 239
 - sulfonamide 584, 586
 - primary analogs of 586
 - sulfur-containing heterocycles 737
 - supercritical fluid chromatography (SFC) 107
 - Super-Star, knowledge-based approach 707
 - surface plasmon resonance (SPR) 21, 48, 120, 404
 - label-enhanced 406
 - Suzuki coupling reaction 557, 754
 - sweet spot 8
 - synthesis weeks 479
 - synthetic chemistry 502
 - art of 502
 - programs 43
 - synthetic feasibility, for generation of screening compounds 107
 - click chemistry 108
 - diversity-oriented synthesis 108, 109
 - – Lewis-acid controlled 109
 - – planning 109
 - multicomponent reactions 107, 108
 - synthetic small molecule 63
 - Sypro Orange dye 412
 - systemic peptide hormone turnover 692
- t**
- tachyphylactic effect 599
 - tadalafil analogs 241
 - TAMRA-labeled peptide substrate 401
 - Tanimoto similarity index 333
 - target-based
 - approach 260, 289
 - campaigns 64
 - drug discovery 38, 43
 - target class analysis, of physical property expansion 342
 - TargetD² assays 310
 - target definition compound (TDC) 48, 405
 - target discovery, chemistry for 71
 - SAR expansion and probe synthesis for target deconvolution 73–75
 - screening deck selection 71, 72
 - triaging and prioritization of chemical matter 72, 73
 - target focus 114
 - target-immobilized NMR spectroscopy (TINS) 47
 - target potency 336–345
 - target product profiles (TPPs) 425, 718
 - for a lead in a project, compound intended for 426
 - tau protein 198, 515
 - TB approved drug
 - bedaquiline 752
 - pyrazinamide 754
 - T2D. *see* type 2 diabetic (T2D)
 - TDI. *see* time-dependent inhibition of Cyp (TDI)
 - template selection 659
 - tenatoprazole 209
 - testosterone 229
 - tethered ligand activation paradigm 551
 - tetrahedral intermediate 694
 - tetrahydrothiopyran derivative 563
 - Raney nickel reduction of 563
 - tetra-valent zanamivir conjugates 670
 - thalidomide 234
 - The Drugs for Neglected Diseases initiative (DNDi) 320, 321
 - therapeutic index (TI) 585
 - thermal shift assay (TSA) 411, 412
 - thermodynamic fingerprint, of ligands 372
 - thermodynamics 367

- of molecular interactions
 - – and impact on hit finding and optimization 369, 370
 - parameters 368
 - thiazole derivatives, *in vitro* properties of 530
 - thiazoles 534
 - Thorpe–Ingold effect 556
 - α -thrombin 553
 - thrombin-induced platelet aggregation, inhibition of 558
 - thrombin receptor 551
 - thrombin receptor-activating peptide (TRAP) 551, 553
 - induced platelet aggregation 557
 - thrombin receptor activation
 - mechanism of 551
 - tethered ligand mechanism of 552
 - thrombin receptor antagonist 562
 - antiplatelet agent 547
 - thrombin receptor antagonist for cardiovascular event reduction in percutaneous coronary interventions study (TRA-PCI) 567
 - thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) 568
 - thrombin receptor antagonists 549
 - antiplatelet effect of 552
 - TI. *see* therapeutic index
 - tiagabine 193
 - time-dependent inhibition of Cyp (TDI) 632
 - time resolved-FRET (TRF) signal 599
 - timoprazole 203
 - TINS (target-immobilized NMR screening) approach 136, 152
 - tipranavir 232
 - tissues 67
 - tolbutamide 232
 - tools, for estimating molecular similarity 428
 - topological polar surface area (TPSA) 342
 - total polar surface area (TPSA) 464
 - toxicity 25, 425
 - toxicological properties 39
 - TPSA. *see* total polar surface area
 - TRACER. *see* thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER)
 - transcription 401
 - transformation-based approaches 440
 - transition state 159, 162, 163, 164
 - analogs 161, 164
 - TRAP. *see* thrombin receptor-activating peptide (TRAP)
 - triazine-based pharmacophore 415
 - triazoles 108
 - synthesis via click chemistry 108
 - tricyclic aldehyde intermediate, synthesis of 555
 - tricyclic carboxylic acid 554, 561
 - tricyclic carboxylic ester 554, 561
 - catalytic hydrogenation of 554
 - tricyclic ring system 547, 556
 - trifluoromethoxybenzyl group, lipophilic 499
 - 3,5-*N*-trihydroxyheptamide moiety 194
 - 1,2,4-trioxolane-containing clinical candidate 319
 - trypsin 551
 - tryptase 551
 - tuberculosis (TB) 717
 - examples of phenotypic screens 733, 736–741
 - – compounds under development 734, 735
 - – overlay of PBTZ169 and TCA1. 738
 - and global alliance for tuberculosis drug development (TB Alliance) 323, 324, 729, 730
 - Hit generation strategies for TB 732
 - target product profiles 730, 731
 - targets of TB drugs and compounds under development 740
 - TB Alliance's Mission 730, 731
 - treatment for drug-sensitive strains 730
 - Tuberculosis Drug Discovery Initiative (TBDDI) 311
 - two-dimensional (2D) quantitative structure–activity relationships (QSAR) methods 429
 - challenges of 429
 - type 2 diabetic (T2D) 598
- u**
- ubiquitin 503
 - C-terminus of 503
 - uLABA. *see* ultralong acting β_2 AR agonist
 - ultralong acting β_2 AR agonist (uLABA) 575
 - urokinase-type plasminogen activator 245
- v**
- van der Waals
 - effects 40
 - interactions 699
 - vertex compounds 505
 - vilanterol 587
 - viloxazine analogs 237
 - vinyl pyridine derivatives 555
 - virtual, combinatorial library 444

virtual libraries 756
 – physicochemical properties of 755
 virtual ligand screen 184
 virtual screening 20, 168, 428, 756
 – in BICLAIM library 172
 virtual screening (VS) 23, 160, 333
 virus replication 667
 visualization tools 23
 vorapaxar 565, 566
 – crystal structure of 551
 – cytochrome P450 (CYP450) enzyme inhibition potential 566
 – discovery of 547
 – effects on aggregation responses to thrombin 565
 – pharmacokinetic profiling of 565
 – structure of 547
 VS. *see* virtual screening (VS)

W

warfarin 232
 water molecule 497
 Web services 428

Wellcome Trust 717
 whole-organism screening 68
 World Bank 717

X

xenobiotic 367
Xenopus laevis 290
 x-ray crystallography 47, 48, 333, 665
 x-ray structure 163, 360
 – -based drug design 187

Y

yeast carboxypeptidase Y 687

Z

zaleplon 229
 zanamavir (RelenzaTM) 161
 zanamivir 163, 658, 667, 668, 669, 675
 Z-factor 291
 zolpidem 229
 zoonotic influenza A viruses 651
 zopiclone 229
 zwitterions 470

